Substitute for form 1449A/PTO INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

ı of 6 Sheet

Application Number 10/010,345 Filing Date December 5, 2001 First Named Inventor A.G. Daifotis Group Art Unit 1617 Examiner Name T.J. Criares Attorney Docket Number 20002YIBCA	\
Filing Date December 5, 2001 First Named Inventor A.G. Daifotis Group Art Unit Examiner Name T.J. Criares	X
First Named Inventor A.G. Daifotis Group Art Unit Examiner Name T.J. Criares	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\
Group Art Unit 1617 JUN 1 9 7002 Fig. 15 Examiner Name T.J. Criares	
Examiner Name T.J. Criares	1
7, 19	6 6 V
and the same of th	85°
Attorney Docket Number 20002YIBCA TRADEMA	100
TENT DOCUMENTS	

			U.S. P	ATENT DOCUMENTS	
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
n		5,270,365		Gertz et al.	12/14/1993
71		5,366,962		Strein	11/22/1994
		4,761,406		Flora et al.	08/02/1988
		4,425,339		Pitchford	01/10/1984 😤 ,
		4,621,077		Rosini et al.	11/04/1986
		5,616,560		Geddes	04/01/1997
		5,780,455		Brenner et al.	07/14/1998
		5,773,429		Fuisz	06/30/1998
		5,488,041		Barbier et al.	11/04/1986 H 9 04/01/1997 H 9 07/14/1998 H 9 06/30/1998 98 01/30/1996 98
		4,980,171		Fels et al.	12/15/1990
		4,812,304		Anderson et al.	03/14/1989
		4,822,609		Flora	04/18/1989
		5,358,941		Bechard et al.	10/25/1994
		5,616,571		Daifotis et al.	04/01/1997
		5,853,759		Katdare et al.	12/29/1998
		5,804,570		Santora II et al.	09/08/1998
		5,583,122		Benedict et al.	12/10/1996
		5,622,721		Dansereau et al.	04/22/1997
		4,927,814		Gall et al.	05/22/1990
7		5,994,329		Daifotis et al.	11/30/1999

	FOREIGN PATENT DOCUMENTS										
				Foreign Patent Document		Foreign Patent Document		Foreign Patent Document			Date of Publication of
Exami Initials	kaminer Cite itials* No. Office Number		Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY						
K	7			WO 95/30421		Goodship et al.	11/16/1995				
				WO 96/17616		Gazard	06/13/1996				
П				WO 94/00129		Francis et al.	01/06/1994				
\Box				WO 94/00130		Hovancik et al.	01/06/1994				
	T			WO 94/21242		D'Souza et al.	09/29/1994				
				WO 95/28145		Shinoda et al.	10/26/1995				
П				EP 0 600 834 A1		Goodship et al.	08/06/1994				
\Box	\top			EP 0 274 158		Ebetino et al.	07/13/1988				
	T			WO 95/08331		Bechard	03/30/1995				
				WO 95/28936		Yates	11/02/199				

Examiner Signature	10	Date Considered	3/1703

_		
4	. i	
•		

INFORMATION DIS	SCLOSURE	Application Number	10/020,345	EC
STATEMENT BY AI				
STATEMENT BY AL	THE LOCALITY	Filing Date	December 5, 2001	OPE
	PLICANI	First Named Inventor	A.G. Daifotis	
		Group Art Unit	1617	JUH 1 9 7002
(use as many sheets as i	necessary)	Examiner Name	T.J. Criares	
Sheet 2 of	6	Attorney Docket Number	20002YIBCA	TRADEM

Cite Number Num	Date of Publication of Cited Document MM-DD-YYYY 07/13/1993 03/14/1989
	03/14/1989
4,812,311 Uchtman	
	RECEIVE
	i e
	JUN 2 5 2002
	TECH CENTER 1600/2

			FOREI	GN PATENT	T DOCUMENTS	
Examiner Initials*	Cite No.	Office	Foreign Patent Documen Number	t Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
	,		WO 96/25166		Merck & Co., Inc.	08/22/1996
N			WO 93/11786		Procter & Gamble Pharm., Inc.	06/24/1993
		<u> </u>	•			
_			·			
		L				
			V		•	

Examiner Signature	pa	Date Considered 3/1/03	

Sheet

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

of

(use a	s many	sneers	us	necessury)
				•

SUBSTITUTE	Approved for us 8A (08-00), Informatic Office	se through 10/31/200 mation Disclosure St U.S DEPARTMEN	02. OMB 0651- latement by Appl NT OF COMME	0031 icant RCE) _^
	COMPLETE IF KNO	WN		一个	^
Application Number	10/010,345		760	160	
Filing Date	December 5, 2001		- 6/4		0, V
First Named Inventor	A.G. Daifotis	TP	E		200
Group Art Unit	1617	/ 0 -	~		1600
Examiner Name ·	T.J. Criares	JUN 1 9	100k		2900
Attorney Docket Number	20002YIBCA	FEE			B

		OTHER NON BATTENE LITTER A THIRE DOCUMENTS
		OTHER NON PATENT LITERATURE DOCUMENTS
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.
W	AA	Lunar News, April 1997, "Update: Bisphosphonate", pp. 30-32
	AB	Gertz et al., Osteoporosis Int. (1993), Suppl. 3: S13-16, "Clinical pharmacology of alendronate sodium"
	AC	Gertz et al., Clin. Pharma. Ther. (1995), Vol. 58, pp. 288-98, "Studies of the oral bioavailability of alendronate"
	AD	de Vernejoul et al., Calcified Tissue Int1, Vol. 40 (1987), pp. 160-165, "Different schedules of administration of (3 amino-1-hydroxypropylidene)-1,1-bisphosphonate induce different changes"
	ΑE	Lufkin et al., Osteoporosis Intl. (1994), Vol. 4, pp. 320-322, "Pamidronate: An unrecognized problem in gastrointestinal tolerability".
	AF	De Groen et al., N. England J. of Medicine, (1996), Vol. 335, pp. 1016-1021, "Esophagitis associated with the use of alendronate"
	AG	Castell, (an editorial), N. England J. of Medicine (1996), Vol. 335, pp. 1058-1059, "Pill esophagitis - the case of alendronate".
	АН	Liberman et al., (correspondence), N. England J. of Medicine (1996), Vol. 335, pp. 1069-1070, "Esophagit and alendronate".
	AI	Chesnut et al., Am. J. of Medicine, Vol. 99 (1995), pp. 144-152, "Alendronate treatment of the postmenopausal osteoporotic woman".
	AJ	Cassidy et al., Digestive Diseases and Sciences, Vol. 37 (1992), pp. 1206-1211, "Continuous verus intermittent acid exposure in production of esophagitis in feline model".
	AK	Mortensen et al., J. of Bone & Mineral Res., (1995) Vol. 10, suppl. 1, p. s140, "Prevention of early postmenopausal bone loss of risendronate".
	AL	Singer et al., Advances in Endocrin.& Metab., Vol. 6 (1995), pp. 259-288, "Bisphosphonates in the treatment of disorders or mineral metabolism".
	AM	Lieberman et al., N. Eng. J. of Medicine, Vol. 333 (1995), pp. 1437-1443, "Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis".
	AN	Bankhurst et al., Arthritis and Rheumatism, Vol. 38, No. 9, Suppl. 1 (1995), S359, "Three-year treatment with alendronate prevents fractures in women with postmenopausal osteoporosis".
	AO	Filipponi et al., J. of Bone & Min. Research, Vol. 10 (1995), pp. 697-703, "Cyclical clondronate is effective in preventing postmenopausal bone loss: A comparative study with transcutaneous hormone replacement therapy".

Date Considered Examiner Signature

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

	- (

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

	Tri-seriasia	SHEE, C.S DELFACTIVEST OF COMME	(CE				
COMPLETE IF KNOWN							
Application Number	10/010,345						
Filing Date	December 5, 200						
First Named Inventor	A.G. Daifotis	OIPE A					
Group Art Unit	1617	This man					
Examiner Name	T.J. Criares	JUH 19 DEC 19					
Attorney Docket Number	20002YIBCA	THE WAR THE STATE OF THE STATE					

I	NFOR	MATION	DISCL	OSURE	Application Number	10/010,345			
STATEMENT BY APPLICANT		Filing Date	December 5, 2001		<u> </u>				
		First Named Inventor	A.G. Daifotis	NPE	78				
					Group Art Unit	1617	2 2000	CA	
	(use as many sheets as necessary)			sary)	Examiner Name	T.J. Criares	70H 1 8 5005		
Sheet		4 of 6			Attorney Docket Number	20002YIBCA	Etter - Cal	I ECO	
OTHER NON PATENT LITERATURE DOCUMENTS									
Examine Initials*	r Cite No.		Include	name of the author,	title, date, page(s), volume-issue	number(s) and place	of publication.		
Group Art Unit Examiner Name T.J. Criares OTHER NON PATENT LITERATURE DOCUMENTS Examiner Initials* No. AP McClung et al., Bone, Vol. 17 (1995), pp. 493S-496S, "Tiludronate therapy for Paget's disease of bone". Seltenmeyer et al., Bone (NY), Vol. 20, No. 4, Suppl., (1997) pp. 114S, "A comparison of the antiresorptive									
	AQ		arious bis	phosphonates in	20, No. 4, Suppl., (1997) pn vivo with their inhibitory				
	AR				ends, Vol. 14, No. 1 (1996) w oral bisphosphonate age		teoporosis its	diagnosis,	
	AS	Bell et al., E	ndocrine,	Vol. 6(2) (199	7), pp. 203-206, "Bisphosp	phonates in the Tr	eatment of Oste	oporosis".	
	AT	Melsen et al.	Melsen et al., Osteoporosis, Chapt. 60(1996), pp. 1145-1158, "ADFR - The Concept and its performance".						
	AU	Thompson et al., J. of Bone & Min. Research, Vol. 7(1992), pp. 951-960, "The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons".							
	AV	Balena et al., J. Clin. Invest., Vol. 92 (1993), pp. 2577-2586, "The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates".							
	AW	Peter et al., Digestive Diseases & Sciences, Vol. 43 (1998), pp. 1009-1015, "Comparative study of potential for bisphosphonates to damage gastric mucosa of rats".							
	AX	Peter et al., Digestive Diseases & Sciences, Vol. 43 (1998), pp. 1998-2002, "Esophageal irritation due to alendronate sodium tablets".							
	AY	Harris et al., J. of Clin. Endoc. & Metab., 76:1399-1406 (1993), "The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone".							
	AZ	Khan et al., I	Bone, Vo	I. 20 (1997), pp	. 263-271, "Alendronate in	the treatment of	Paget's disease of	of bone".	
	ВА	Physician's E	Desk Refe	rence, 51st ed. ((1997), pp. 1703-1706, "F	osamax".			
	ВВ		Gertz et al., J. of Bone & Min. Res., Vol. 9 (1994), pp 135-142, "Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine".						
	вс	Fleisch, J. of Clin. Endoc. & Metab., Vol. 76 (1993), pp. 1397-1398, "Editorial: Prospective use of bisphosphonates in osteoporosis".							
V	BD		Chesnut et al., Osteoporosis Int1 (1993), Suppl. 3: S17-19, "Short-term effect of alendronate on bone mass and bone remodeling in postmenopausal women".						
		L							

Examiner Signature	AC.

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date Considered

a plus si	gn (+ ·) inside this box		+		SUBSTITUTE	Approved for SA (08-00), In Par Trademark Of	r use through 10/31/2002. OMB 0651-0031 formation Disclosure Statement by Applicant fice; U.S DEPARTMENT OF COMMERCE
Substitute for form 1449A/PTO								
INFORMATION DISCLOSURE					Application Number	10/010,345		
STATEMENT BY APPLICANT			Filing Date	December 5, 2001	۸.			
			First Named Inventor	A.G. Daifotis	OPE CH			
						Group Art Unit	1617	10 300
(use as many sheets as necessary)				Examiner Name	T.J. Criares	JUH 1 9 2002 15		
		5	of	6		Attorney Docket Number	20002YIBCA	JUN 1 9 ZOOZ 15
			OT	HER NON I	PATE	NT LITERATURE DO	CUMENTS	PANCE
			Includ	le name of the a	uthor, t	itle, date, page(s), volume-issu	number(s) and place of	•
	:	and dose proj	J. of Bo portion	ne & Min. R ality of alend	es., V Ironat	ol. 6, Suppl. 1 (1991), A e (aminohydroxybutylidd	bstract No. 790, p ene bisphosphonat	. S281, "Oral bioavailability e) in postmenopausal
BF		Mortensen et al., J. Bone & Min. Res., (1995), 10 (Supp. 1): S360, "Prevention of early postmenopausal bone loss by residronate: A two year study".						
ВС	;	Actonel™ (risedronate sodium tablets) package insert, dated March 1998. RECEIVED						
BF	I	Lunar News (July 1996), "Update: Bisphosphonate", pp. 23-24						
ві		Lunar News (April 1996), "Update: Bisphosphonate", p. 31						
ВЈ		The Pink Sheet (Dec. 18, 1995), Vol. 57, Issue 51, "Merck Cozaar generating 25,000 scripts weekly after six months on market; Foxamax off to quick start, company tells securities analyst meeting".						
вк		Scrip (11/24/	/99), "M	1erck develo	ps one	e-weekly Fosamax".		
BL						h 2001), pp. 28-32, "Osi	eoporosis: Effica	cy and safety of a
ВМ		Bone et al., Clinical Therapeutics, Vol. 22, No. 1 (2000), pp. 15-28, "Weekly administration of alendronate: Rationale and plan for clinical assessment".						
BN		Fleisch, Expert Opinion Therapeutic Patents, Vol. 11, No. 9 (2000), p. 1371-1381, "Bisphosphonates: mechanisms of action".						
ВС)	Peter et al., Journal of Pharmacology & Experimental Therapeutics, Vol. 276, No. 1 (1996), p. 271-276, "Long-term safety of the aminobisphosphonate alendronate in adult dogs".						
ВР		Rodan et al., Osteoporosis International (1993) Suppl., 3:S7-12, "Preclinical Pharmacology of alendronate".						
вС		Schnitzer, Expert Opinion Pharmacother., Vol. 2, No. 9 (2001), pp. 1461-1472, "Update on alendronate for osteoporosis: once-weekly dosing".						
BR		equivalence o	of alend	ng: Clinical Ironate 70 m	and E g once	xperimental Research, V -weekly and alendronate	ol. 12, No. 1 (200 e 10 mg daily in th	0), P. 1-12, "Therapeutic e treatment of
BS		Seedor et al.,	Journa					-346, "The bisphosphonate
	BE B	BE BF BG BH BI BI BI BN BO BP BQ BR	BE and dose prowomen". BF Mone loss by BG Actonel M Connection of the Prink She months on m BK Scrip (11/24/24/24/24/24/24/24/25/24/25/24/25/24/25/24/25/24/25/24/25/25/25/25/25/25/25/25/25/25/25/25/25/	Substitute for form 1449A/PTO INFORMATION DISC STATEMENT BY APP (use as many sheets as necessary sheets a	STATEMENT BY APPLICANT (use as many sheets as necessary) 5	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 5	INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) The Pink Sheet (Dec. 18, 1995), Vol. 57, Issue 51, "Merck Coamonths on market; Foxamax off to quick start, company tells see hisphosphonate", p. 31 The Pink Sheet (Dec. 18, 1995), Vol. 57, Issue 51, "Merck Coamonths on market; Foxamax off to quick start, company tells see hisphosphonate dosed once-weekly Fosamax". BY Baran, Geratrics, Vol. 56, No. 3 (March 2001), pp. 28-32, "Ost bisphosphonate dosed once weekly". BY Baran, Geratrics, Vol. 56, No. 3 (March 2001), pp. 28-32, "Ost bisphosphonate dosed once weekly". BY Peter et al., Journal of Pharmacology & Experimental Therapeutic Patents, Vol. 11, No. 9 (2001) osteoporosis: once-weekly dosing". BY Rodan et al., Osteoporosis International (1993) Suppl., 3:S7-12 BY Schnitzer et al., Aging: Clinical and Experimental Research, Vol. 58, Rod. Science, Vol. 29, No. 1 (2000) pp. 18 BY Rodan et al., Osteoporosis International (1993) Suppl., 3:S7-12 BY Schnitzer et al., Aging: Clinical and Experimental Research, Vol. 20, No. 20, 20, No. 40, No. 50, No. 3 (March 2001) pp. 2001) osteoporosis: once-weekly dosing". BY Schnitzer et al., Aging: Clinical and Experimental Research, Vol. 60, No. 50, Seedor et al., Journal of Bone & Mineral Research, Vol. 60, No. 50, Seedor et al., Journal of Bone & Mineral Research, Vol. 60, No. 50, Seedor et al., Journal of Bone & Mineral Research, Vol. 60, No. 50, Seedor et al., Journal of Bone & Mineral Research, Vol. 60, No. 50, Seedor et al., Journal of Bone & Mineral Research, Vol. 60, No. 50, Seedor et al., Journal of Bone & Mineral Research, Vol. 60, No. 50, Seedor et al., Journal of Bone & Mineral Research, Vol. 60, No. 50, Seedor et al., Journal of Bone & Mineral Research, Vol. 60, No. 50, Seedor et al., Journal of Bone & Mineral Research, Vol. 60, No. 50, Seedor et al., Journal of Bone & Mineral Research, Vol. 60, No. 50, Seedor et al., Journal of Bone & Mineral Research, Vol. 60, No. 50, Seedor et al., Journal of Bone & Mineral Research, Vol. 60,	COMPLETE IF KN INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) 5 of 6 Attorney Docket Number 5 of 6 Attorney Docket Number TJ. Criares Total Care and dose proportionality of alendronate (aminohydroxyburylidene bisphosphonate months on market; Foxamax off to quick start, company tells securities analyst months on market; Foxamax off to quick start, company tells securities analyst months on market; Foxamax off to quick start, company tells securities analyst months on market; Foxamax off to quick start, company tells securities analyst months on factorion. BY BY BY Comparison of the author, title, date, page(s), volume-issue number(s) and place to the page (s), volume-issue number(s) and place to many and dose proportionality of alendronate (aminohydroxyburylidene bisphosphonate women." BY Mortensen et al., J. of Bone & Min. Res., (1995), 10 (Suppl. 1 (1991), Abstract No. 790, p and dose proportionality of alendronate (aminohydroxyburylidene bisphosphonate bone loss by residronate: A two year study". BY Mortensen et al., J. Bone & Min. Res., (1995), 10 (Suppl. 1): S360, "Prevention of bone loss by residronate sodium tablets) package insert, dated March 1998. BH Lunar News (April 1996), "Update: Bisphosphonate", pp. 23-24 BI Lunar News (April 1996), "Update: Bisphosphonate", pp. 23-24 BI BJ The Pink Sheet (Dec. 18, 1995), Vol. 57, Issue 51, "Merck Cozaar generating 25 months on market; Foxamax off to quick start, company tells securities analyst months on market; Foxamax off to quick start, company tells securities analyst months on market; Foxamax off to quick start, company tells securities analyst months on market; Foxamax off to quick start, company tells securities analyst months on market; Foxamax off to quick start, company tells securities analyst months on market; Foxamax off to quick start, company tells securities analyst months on market; Foxamax off to quick start, company tells securities analyst months on market; Foxamax off to quick start, compan

Examiner Signature Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

Sheet

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Examiner Name Attorney Docket Number

COMPLETE IF KNOWN 10/020,345 **Application Number** Filing Date December 5, 2001 First Named Inventor A.G. Daifotis Group Art Unit 1617 T.J. Criares 20002YIBCA

1	icci		This is a second of the second									
			OTHER NON PATENT LITERATURE DOCUMENTS									
	miner ials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.									
P	pe BT		Sorrentino, Endoscopy, Vol. 28 (1996), p. 529, "Esophageal ulceration due to alendronate".									
		вU	Blank, American College of Gastroenterology 66th Annual Scientific Meeting, "Lack of gastric adaptation to weekly versus daily alendronate administration in rats".									
		BV	Bone et al., Journal of Bone & Mineral Research, Vol. 16, Suppl. 1 (September 2001), M392, "Once-weekly alendronate: Two year subgroup efficacy analyses in postmenopausal women with osteoporosis".									
/		BW	Bone III et al., 6th International Symposium on Clinical Disorders of Bone and Mineral Metabolism, Venice, Italy, November 20-25, 1999, "Alendronate 70 mg once weekly is therapeutically equivalent to alendronate in 10 mg daily".									
		BX	Brown et al., Journal of Bone & Mineral Research, Vol. 16, Suppl. 1 (September 2001), M402, "Efficacy, safety and tolerability of once weekly (80 mg vs. 160 mg) oral alendronate in postmeopausal osteoporosis".									
		BY	Delaney et al., ENDO 2001, The Endocrine Society's 83rd Annual Meeting, Denver, Colorado (June 2001), Abstract, P1-469 (June 2001), p. 249, "Bone density changes in response to risedronate once weekly".									
		BZ .	Gordon et al., ENDO 2001, The Endocrine Society's 83rd Annual Meeting, Denver, Colorado (June 2001), Abstract, P1-460 (June 2001), p. 247, "Weekly administration of risedronate increase bone mineral density".									
		CA	Lindsay et al., Arthritis & Rheumatism, Vo. 44, No. 9 (Suppl.), Abstract No. 604, "Risedronate 35 mg once a week is as effective as 5 mg daily in postmenopausal women".									
		СВ	Rizzoli et al., Journal of Bone & Mineral Research, Vol. 16, Suppl. 1 (September 2001), M401, "Two year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis".									
		CC	Rizzoli et al., Annals of the Rheumatic Diseases, Annual European Congress of Rheumatology, EULAR 2001, Prague, Czech Republic, Vol. 60, Suppl. 1 (July 2001), Abstract SAT0164, p. 256, "Two year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis".									
		CD	Van Dyke, et al., Annals of the Rheumatic Diseases, Annual European Congress of Rheumatology, EULAR 2001, Prague, Czech Republic, Vol. 60, Suppl. 1 (July 2001), Abstract SAT0167, p. 256, "Safety of once-weekly alendronate 70 mg in periodontal disease".									
		CE	Wimalawansa, Journal of Bone & Mineral Research, Vol. 16, Suppl. 1 (September 2001), Abstract SA352, "Once a week alendronate therapy: A convenient and effective way of prevention and treatment of osteoporosis: A four-year clinical study".									
		CF	Wimalawansa, Journal of Bone & Mineral Research, Vol. 16, Suppl. 1 (September 2001), Abstract SU399, "Efficacy of once a week risedronate in comparison with once-weekly alendronate therapy for postmenopausal osteoporosis: One-year data".									
		CG	Wimalawansa, ENDO 2001, The Endocrine Society's 83rd Annual Meeting, Denver, Colorado (June 2001), Abstract P1-438, p. 241-242, "Highly efficacious and cost-effective alendronate regimen for postmenopausal osteoporosis: A four-year clinical study"									
1	/	СН	Woodson, Osteoporosis International, Vol. 11, Suppl. 2 (2000), Chicago, Illinois, p. S204, Abstract 550 (514), "Once weekly risedronate therapy".									

Examiner Signature	pa	Date Considered	3/5/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.